Journey Medical Corporation (DERM) vs OptimizeRx Corp. (OPRX)

A side-by-side comparison of Journey Medical Corporation and OptimizeRx Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DERM vs OPRX

growth of $100 · dividends reinvested · last 5y
DERM -29.6% (-6.8%/yr)OPRX -90.0% (-36.9%/yr)DERM compounded faster over this window
Log scale — wide-divergence pair
110100Start $10020222023202420252026$70$10
DERM OPRX

DERM vs OPRX: by the numbers

  • •DERM is the larger company ($173M vs $166M market cap).
  • •OPRX is profitable (4.66% net margin) while DERM runs a net loss (-8.95%).
  • •OPRX grew revenue faster over the past five years (13.75% vs 6.75% CAGR).

Metrics side by side

Valuation

MetricDERMOPRX
P/E ratioN/A37.87
Forward P/EN/A9.87
P/S ratio2.541.68
P/B ratio5.401.27
EV / EBITDA137.2510.45
FCF yieldN/A11.06%

Profitability

MetricDERMOPRX
Gross margin62.24%63.30%
Operating margin-13.21%11.45%
Net margin-8.95%4.66%
ROE-19.01%3.51%
ROIC-5.22%4.92%

Growth (annualized)

MetricDERMOPRX
Revenue CAGR (5Y)6.75%13.75%
Total return CAGR (5Y)N/A-36.23%

Frequently asked

Which has grown faster, DERM or OPRX?
Over the past five years, OPRX grew revenue faster — DERM at a 6.75% CAGR versus OPRX at 13.75%.
Is DERM or OPRX more profitable?
OPRX runs the higher net margin — DERM at -8.95% versus OPRX at 4.66%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.